Biochemical markers of various subtypes of gestational diabetes
- Autores: Volkova N.I.1, Degtyareva Y.S.1, Davidenko I.Y.1, Degtyareva Y.S.1, Avrutskaya V.V.1
-
Afiliações:
- Rostov State Medical University
- Edição: Volume 30, Nº 12 (2023)
- Páginas: 65-70
- Seção: Original articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/626040
- DOI: https://doi.org/10.18565/pharmateca.2023.12.65-70
- ID: 626040
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Background. The prevalence and severity of complications of gestational diabetes (GD) remain a significant problem worldwide. The desire to improve pregnancy outcomes; as well as an understanding of carbohydrate metabolism disorders; has led to studies demonstrating the presence of various pathogenetic subtypes of GD. Thus; studies have already demonstrated that pregnant women with GD and severe insulin resistance (IR) not only have more unfavorable prognoses; but also differ phenotypically and biochemically. Identification of biochemical markers of different GD subtypes has the potential to improve early diagnosis of a specific subtype and personalize treatment depending on the predominant pathogenetic factor.
Objective. Determineation of the biochemical markers for the diagnosis of various GD subtypes in pregnant women.
Methods. A single-center; observational; prospective; uncontrolled study included 130 pregnant women undergoing outpatient examination between March 2020 and March 2022. Based on the results of an oral glucose tolerance test with 75 g of glucose; 88 patients were diagnosed with GD: 43 were diagnosed with GD subtype with impaired β function-cells (GD I); 45 had the GD subtype with predominant IR (GD II); 42 patients formed the control group. Additionally; insulin was determined at three points to calculate the Matsuda index; fasting levels of total cholesterol (TC); triglycerides (TG); high and low density lipoproteins (LDL); apolipoprotein A (Apo-A); apolipoprotein B (Apo-B); adiponectin; leptin and omentin were examined
Results. Pregnant women from the GD II group had statistically significantly higher TG values (P=0.01 when compared with the GD I group; P<0.001 when compared with the control group); the total cholesterol and LDL levels were higher compared to those in patients from other groups; but these changes were not statistically significant. The (Apo-A) level was significantly higher in patients with GD (P<0.001 when comparing both GD groups with the control group) and did not differ when comparing different GD subtypes; in contrast to the Apo-B level; which was significantly higher in pregnant women from the group GD II compared with that in pregnant women from the other two groups (in both cases P=0.02). When studying adiponectin; leptin and omentin; statistically significant differences were detected only in the level of adiponectin (the lowest level in pregnant women from the GD II group compared with participants in other groups; P<0.001 when compared with the GD I group; P=0.004 – with the control group ). It was not possible to detect significant differences in omentin and leptin levels within the study.
Conclusion. High levels of Apo-B; TG; and low levels of adiponectin can be used as potential biomarkers in scientific and clinical practice to verify the pathogenetic subtype of GD with severe IR; most unfavorable factor regarding the prognosis according to previous studies.
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
N. Volkova
Rostov State Medical University
Email: i.s.degtiareva@gmail.com
ORCID ID: 0000-0003-4874-7835
Rússia, Rostov-on-Don
Yulia Degtyareva
Rostov State Medical University
Autor responsável pela correspondência
Email: i.s.degtiareva@gmail.com
Junior Researcher, Department of Internal Diseases №3
Rússia, Rostov-on-DonI. Davidenko
Rostov State Medical University
Email: i.s.degtiareva@gmail.com
ORCID ID: 0000-0002-8690-681X
Rússia, Rostov-on-Don
Yu. Degtyareva
Rostov State Medical University
Email: i.s.degtiareva@gmail.com
Rússia, Rostov-on-Don
V. Avrutskaya
Rostov State Medical University
Email: i.s.degtiareva@gmail.com
ORCID ID: 0000-0001-6399-5007
Rússia, Rostov-on-Don
Bibliografia
- Ye W.; Luo C.; Huang J.; et al. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2022;377:e067946. doi: 10.1136/bmj-2021-067946.
- Metzger B.E.; Gabbe S.G.; Persson B.; et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diab Care. 2010;33(3):676–82.
- World Health Organisation.Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization guideline. Diab Res Clin Pract. 2014;103(3):341–63.
- American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diab Care. 2018;41(Suppl. 1):S13–27.
- Blumer I.; Hadar E.; Hadden D.R.; et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227–49.
- Hod M.; Kapur A.; Sacks D.A.; et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis; management; and care. Int J Gynaecol Obstet. 2015;131(Suppl. 3):S173–211.
- Дедов И.И.; Шестакова М.В.; Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск. Сахарный диабет. 2019;22(Suppl. 1–1):1–144. Dedov I.I.; Shestakova M.V.; Mayorov A.Yu. (ed.). [Algorithms for specialized medical care for patients with diabetes. 9th issue. diabetes mellitus. 2019;22(Suppl. 1–1):1–144. (In Russ.)].
- Sweeting A.; Wong J.; Murphy H.R.; et al. Clin Update Gestat Diab Mellit Endocrine Rev. 2022;43(5):763–93. doi: 10.1210/endrev/bnac003.
- URL: https://www.idf.org/our-activities/care-prevention/gdm
- Powe C.; Allard C.; Battista M.; et al. Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus: Table 1. Diab Care. 2016;39(6):1052–55.
- Liu Y.; Hou W.; Meng X.; et al. Heterogeneity of insulin resistance and beta cell dysfunction in gestational diabetes mellitus: a prospective cohort study of perinatal outcomes. J Translat Med. 2018;16(1).
- Feghali M.; Atlass J.; Ribar E.; et al. 82: Subtypes of gestational diabetes mellitus based on mechanisms of hyperglycemia. Am J Obstet Gynecol. 2019;220(1):S66.
- Benhalima K.; Van Crombrugge P.; Moyson C.; et al. Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. Diabetol. 2019;62(11): 2118–28.
- Волкова Н.И.; Давиденко И.Ю.; Дегтярева Ю.С. Гестационный сахарный диабет. Акушерство и гинекология. 2021;9:174–79. [Volkova N.I.; Davidenko I.Yu.; Degtyareva Yu.S. Gestational diabetes mellitus. Akush Ginekol. 2021;9:174–79. (In Russ.)]. doi: 10.18565/aig.2021. 9.174-179.
- Волкова Н.И.; Давиденко И.Ю.; Сорокина Ю.А. и др. Методы оценки инсулинорезистентности при гестационном сахарном диабете. Медицинский вестник Юга России. 2022;13(1):5–12. [Volkova N.I.; Davidenko I.Yu.; Sorokina Yu.A.; et al. Methods for assessing insulin resistance in gestational diabetes mellitus. Med Herald of the South of Russia. 2022;13(1):5–12. (In Russ.)]. doi: 10.21886/2219-8075-2022-13-1-5-12.
- Rahnemaei F.A.; Pakzad R.; Amirian A.; et al. Effect of gestational diabetes mellitus on lipid profile: A systematic review and meta-analysis. Open Med. 2021;17(1):70–86. doi: 10.1515/med-2021-0408.
- Anjum F.; Rana Z.; Ashjan S.; et al. Glycated hemoglobin and Lipid Profile Association among pregnant women in Saudi Arabian population. Int. J. Women’s Health and Reproduct. Sci. 2018;7(2):216–22. doi: 10.15296/ijwhr.2019.36.
- Layton J.; Powe C.; Allard C.; et al. Maternal lipid profile differs by gestational diabetes physiologic subtype. Metab. 2019;91:39–42. doi: 10.1016/j.metabol.2018.11.008.
- Mohammadi T.; Paknahad Z. Adiponectin concentration in gestational diabetic women: A case-control study. Clin Nutr Res. 2017;6(4):267. doi: 10.7762/cnr.2017.6.4.267.
- Florian A.; Cruciat G.; Pop R.; et al. Predictive role of altered leptin; adiponectin and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid secretion in gestational diabetes mellitus. Exp Ther Med. 2021;21(5). doi: 10.3892/etm.2021.9951.
- Franz M.; Polterauer M.; Springer S.; et al. Maternal and neonatal omentin-1 levels in gestational diabetes. Arch Gynecol Obstet. 2018;297(4):885–89. doi: 10.1007/s00404-018-4652-5.
Arquivos suplementares
![](/img/style/loading.gif)